Platelet Biochemistry and Morphology after Cryopreservation

Six, Katrijn R.; Compernolle, Veerle; Feys, Hendrik B.

doi:10.3390/ijms21030935

Cited by 19 publications

(13 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36 Cryopreserved PLTs express high levels of phosphatidylserine and have more phosphatidylserine-positive microparticles than PLTs stored at room temperature. 35 In fact, the increased microparticle content induced by cryopreservation provides an extra surface area for coagulation factor/complex adhesion, 31 and PLT-derived microparticles are 50-to 100-fold more procoagulant than activated PLTs alone. 37 Furthermore, microparticles formed during cryopreservation could be biochemically better prepared for catalyzing coagulation reactions.…”

Section: Discussionmentioning

confidence: 99%

“…On the one hand, PLT recovery is greatly influenced by PLT losses during handling, including in the supernatant removal in the cryopreservation and reconstitution method. Some authors 31 state that around 12.5% (±2.1) of PLTs is lost in the supernatant during the hyperconcentration step of the “no‐wash” protocol of Valeri 15 . On the other hand, to prevent aggregation, we added ACD‐A at the beginning of the cryopreservation procedure.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cryopreservation of platelets treated with riboflavin and UV light and stored at −80°C for 1 year

et al. 2021

View full text Add to dashboard Cite

Background The combination of pathogen reduction technologies (PRTs) and cryopreservation can contribute to building a safe and durable platelet (PLT) inventory. Information about cryopreserved riboflavin and UV light‐treated PLTs is scarce. Study Design and Methods Twenty‐four buffy coat (BC) PLT concentrates were grouped into 12 type‐matched pairs, pooled, and divided into 12 non‐PRT‐treated control units and 12 riboflavin and UV light PRT‐treated test units. Both were cryopreserved with 5% DMSO and stored at −80°C for 1 year. The cryopreservation method used was designed to avoid the formation of aggregates. PLT variables (PLT recovery, swirling, pH, MPV, and LDH) and hemostatic function measured by thromboelastography (TEG) were analyzed before cryopreservation (day 1) and post‐cryopreservation at day 14 and months 3, 6, and 12 of storage at −80°C. The analyses were carried out within 1‐h post‐thaw. Results No aggregates were found in either PLT group at any time. Swirling was observed in both groups. MPV increased and mean pH values decreased over time (p < .001), but the mean pH value was never below 6.4 in either group after 12 months of storage at −80°C. PLT recovery was good and clotting time became significantly shorter over the storage period in both groups (p < .001). Conclusion Our cryopreservation and thawing method prevented aggregate formation in cryopreserved riboflavin‐UV‐light‐treated PLTs, which exhibited good recovery, swirling, pH > 6.4, and procoagulant potential, as evidenced by a reduced clotting time after 12 months of storage at −80°C. The clinical relevance of these findings should be further investigated in clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cryopreservation of platelets treated with riboflavin and UV light and stored at −80°C for 1 year

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Assessment of coagulopathy in cancer and hematologic disorders remains an open and promising field, with expansion of whole blood-based technologies. 113,[114][115][116] However, unless randomized controlled trials are conducted in the future, little progress can be made. The same situation occurred a decade ago with the use of VETs to guide blood component therapy in a goal-directed fashion in trauma resuscitation.…”

Section: Discussionmentioning

confidence: 99%

Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): Review of existing evidence, technology comparison, and clinical utility

et al. 2020

View full text Add to dashboard Cite

The quantification of the coagulopathic state associated with oncologic and hematologic diseases is imperfectly assessed by common coagulation tests such as prothrombin time, activated partial thromboplastin time, fibrinogen levels, and platelet count. These tests provide a static representation of a component of hemostatic integrity, presenting an incomplete picture of coagulation in these patients. Viscoelastic tests (VETs), such as rotational thromboelastometry (ROTEM) and thromboelastography (TEG), as whole blood analyses, provide data related to the cumulative effects of blood components and all stages of the coagulation and fibrinolytic processes. The utility of VETs has been demonstrated since the late 1960s in guiding blood component therapy for patients undergoing liver transplantation. Since then, the scope of viscoelastic testing has expanded to become routinely used for cardiac surgery, obstetrics, and trauma. In the past decade, VETs' expanded usage has been most significant in trauma resuscitation. However, use of VETs for patients with malignancy‐associated coagulopathy (MAC) and hematologic malignancies is increasing. For the purposes of this narrative review, we discuss the similarities between trauma‐induced coagulopathy (TIC) and MAC. These similarities center on the thrombomodulin‐thrombin complex as it switches between the thrombin‐activatable fibrinolysis inhibitor coagulation pathway and activating the protein C anticoagulation pathway. This produces a spectrum of coagulopathy and fibrinolytic alterations ranging from shutdown to hyperfibrinolysis that are common to TIC, MAC, and hematologic malignancies. There is expanding literature regarding the utility of TEG and ROTEM to describe the hemostatic integrity of patients with oncologic and hematologic conditions, which we review here.

show abstract

“…The manufacturing and storing of concentrated platelet components need to pay attention to standards and quality control because, during the storage period, changes in the structure and function of platelets can occur, which may result in damage to the components of the concentrated platelets ( (Jain A, Neelam Marwaha, Ratti Ram Sharma, Jyotdeep Kaur, 2015;Diyanti, Luh Putu Sukma, 2017). In vivo storage of platelets can stimulate changes in biochemical and platelet function called a platelet storage lesion (Six, Compernolle and Feys, 2020).…”

Section: Introductionmentioning

confidence: 99%

Platelet Morphological Assessment Based on Shelf-Life of Concentrated Platelet Components

Astuti¹,

Maharani²,

Susadma³

2021

biomedika

View full text Add to dashboard Cite

Concentrated platelet components are the components or platelets that are processed through centrifugation from whole blood or a single donor. The components of the concentrate platelets are stored in an agitator at a temperature of 20-24◦C with a maximum shelf-life of five days. During the storage, a change in component metabolism occurs, which is characterized by alteration in platelet morphology as an indicator of decreasing quality of platelet components. The purpose of this study was to determine the quality of the components of platelets based on the shelf-life by measuring the platelet morphological values with the Kunicki method. This study applied an experimental method by conducting inspections of the regional blood transfusion unit (UTDD) of the Indonesian Red Cross of Jakarta Capital Special Region (PMI DKI Jakarta). Platelet morphological values of six components of platelets were examined by the Kunicki method on day 0 to day 5 of shelf-life. Quality assessment was carried out based on a significant difference-dependent t-test and comparison with normal value. The results of the study by performing statistical analysis of the significant difference-dependent t-test showed a significant difference of values between day 0 and day 1 to day 5 of shelf-life. Comparison with normal values depicted that all samples stored on day 4 had a morphological value of more than 200. On day 5 of shelf-life, the platelet morphology values of five samples were below 200. The quality of the concentrated platelet components is said “good” if it is above 200. This study concluded that there was a significant difference in the platelet morphology values between the components of concentrated platelets on day 0 and day 1 to day 5 of shelf-life. All samples were of good quality until day 4 of storage. However, on day 5 of storage, only one sample was good in quality.

show abstract

Platelet Biochemistry and Morphology after Cryopreservation

Cited by 19 publications

References 60 publications

Cryopreservation of platelets treated with riboflavin and UV light and stored at −80°C for 1 year

Cryopreservation of platelets treated with riboflavin and UV light and stored at −80°C for 1 year

Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): Review of existing evidence, technology comparison, and clinical utility

Platelet Morphological Assessment Based on Shelf-Life of Concentrated Platelet Components

Contact Info

Product

Resources

About